Results 161 to 170 of about 20,131,715 (394)

Benefit‐risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation [PDF]

, 2017
Kimberly Struble, Kirk M. Chan‐Tack, Karen Qi, Lisa K. Naeger, Debra Birnkrant   +4 more
openalex   +1 more source

On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017 [PDF]

, 2020
Christer Frode, Jørn Henrik Vold, Svetlana Skurtveit, Ingvild Odsbu, Fatemeh Chalabianloo, Jan Magnus Økland, Rafael Alexander Modahl Leiva, Peter Vickerman, Kjell Arne Johansson, Lars Thore Fadnes   +9 more
openalex   +1 more source

EASL Recommendations on Treatment of Hepatitis C 2018.

Journal of Hepatology, 2018
J. Pawlotsky, A. Aghemo, G. Dusheiko, X. Forns, M. Puoti, C. Sarrazin   +5 more
semanticscholar   +1 more source

Investigation into the Pancreatic Pathogenesis of SFTSV across Multiple Levels

Advanced Science, EarlyView.
A retrospective analysis revealed that 17.6% of severe fever with thrombocytopenia syndrome (SFTS) patients met the diagnostic criteria for clinically confirmed pancreatitis. Using human pancreatic organoids and murine models demonstrated that SFTSV exhibits a specific pancreatic tropism, leading to cell death and initiating a strong inflammatory ...
Xiaohan Liu, Zhihao Xu, Yilun Tong, Changtai Wang, Yueqi Yao, Yujie Diao, Jingyuan Ma, Shijun Zhou, Yinan Du, Zhenhua Zhang, Gang Xu   +10 more
wiley   +1 more source

GSDMD induces hepatocyte pyroptosis to trigger alcoholic hepatitis through modulating mitochondrial dysfunction

Cell Division
Background Mechanisms and consequences of Gasdermin D (GSDMD) activation in alcoholic hepatitis (AH) are unclear. In the present study, we investigated whether GSDMD induces hepatocyte pyroptosis by regulating mitochondrial dysfunction in AH.
Yandi Xie, Zilong Wang, Guangjun Song, Hui Ma, Bo Feng   +4 more
doaj   +1 more source

RNAi Regulator C3PO Promotes Arbovirus Infection in Insect Vectors

Advanced Science, EarlyView.
RNA interference (RNAi) is vital for eukaryotes to defend against virus infection. The C3PO complex takes part in RNAi but its role in regulating viral infection remains unclear. This work finds that insect C3PO facilitates arbovirus replication by degrading precursors of miRNAs, especially miR‐971‐3p.
Yan Xiao, Tianyu Guan, Qianfeng Xia, Chen Chen, Qian Wang, Lan Luo, Hong Lu, Feng Cui   +7 more
wiley   +1 more source

Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients

The Korean Journal of Gastroenterology
Background/Aims: This study assessed the long-term efficacy and safety of tenofovir alafenamide (TAF) in real-world settings. Methods: Patients who were candidates for TAF treatment and were followed up at 12-week intervals over 192 weeks were enrolled ...
Yu-Xuan Song, Guang-Jun Song, Hui Ma, Bo Feng, Yan-Di Xie   +4 more
doaj   +1 more source

Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs

, 2001
Thomas Pietschmann, Volker Lohmann, Gabriel Rütter, Katharina Kurpanek, Ralf Bartenschlager   +4 more
openalex   +1 more source

Boron Nitride Nanomaterials Trigger Immunomodulatory Effects in Human Broncho‐Epithelial Cells by Modulating Eicosanoid Lipid Signaling

Advanced Science, EarlyView.
This study demonstrates that BNNT exposure disrupts lipid homeostasis in bronchial epithelial cell cultures and activates eicosanoid lipid biosynthesis, producing inflammatory lipid mediators like leukotrienes. These effects are more pronounced in asthmatic cell cultures compared to healthy ones.
Govind Gupta, Jonas Bossart, Sènan Mickael D'Almeida, Luis Augusto Visani de Luna, Christoph Schwärzler, Tingting Fu, Vanesa Ayala‐Nunez, Alexander Gogos, Marija Buljan, Vera M Kissling, Emmanuel Flahaut, Miguel Garcia, Cyrill Bussy, Peter Wick, Tina Buerki‐Thurnherr   +14 more
wiley   +1 more source

Beyond the Hype: What Sofosbuvir Means - and Doesn't - for Global Hepatitis C Treatment [PDF]

, 2013
In December 2013, authorities in the United States and Europe approved Gilead's highly anticipated hepatitis C drug, sofosbuvir. This drug and other new treatments for hepatitis C, called direct-acting antivirals (DAAs), have created a buzz among medical
A. Momenghalibaf
core